PCSK9 and coronary artery disorder: Advancements in lipid-lowering therapies beyond traditional statins for managing coronary artery disease (CAD), like proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (evolocumab and alirocumab), effectively reduce LDL cholesterol levels and lower cardiovascular risk, particularly in patients intolerant to statins [87,88].